Rocket Pharmaceuticals (RCKT) Current Leases: 2019-2025
Historic Current Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Sep 2025 value amounting to $1.9 million.
- Rocket Pharmaceuticals' Current Leases rose 2.99% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of $1.9 million for FY2024, which is 3.63% up from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Current Leases is $1.9 million, which was up 0.69% from $1.9 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Current Leases registered a high of $1.9 million during Q3 2025, and its lowest value of $1.7 million during Q1 2021.
- Over the past 3 years, Rocket Pharmaceuticals' median Current Leases value was $1.8 million (recorded in 2024), while the average stood at $1.8 million.
- Data for Rocket Pharmaceuticals' Current Leases shows a peak YoY climbed of 11.98% (in 2021) over the last 5 years.
- Rocket Pharmaceuticals' Current Leases (Quarterly) stood at $1.7 million in 2021, then increased by 2.78% to $1.7 million in 2022, then climbed by 3.17% to $1.8 million in 2023, then grew by 3.63% to $1.9 million in 2024, then climbed by 2.99% to $1.9 million in 2025.
- Its Current Leases stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.9 million for Q1 2025.